Physician profile
Larry E Shores
NPI 1518093715
$1,716.56
in general payments reported to CMS, 2019-2025
16 companies · $252 in 2025
The $252 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312 · 2020: $163 · 2021: $134 · 2022: $393 · 2023: $352 · 2024: $110 · 2025: $252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $614 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $614.48 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $544.72 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Alkermes, INC. | $272.42 | 2019-2024 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $202.21 | 2019-2023 | Invega Sustenna, Invega Trinza, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $158.36 | 2021-2025 | Caplyta |
| Abbvie INC. | $131.38 | 2021-2025 | |
| Lundbeck LLC | $91.59 | 2019-2023 | Rexulti |
| Vanda Pharmaceuticals INC. | $66.69 | 2022-2023 | Hetlioz, Fanapt |
| Allergan, INC. | $59.98 | 2020 | |
| Sunovion Pharmaceuticals INC. | $50.88 | 2020-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $41.26 | 2022 | |
| Mdd US Operations, LLC | $26.96 | 2019 | |
| Axsome Therapeutics, INC. | $17.84 | 2025 | Auvelity |
| Indivior INC. | $13.81 | 2023 | Perseris |
| Teva Pharmaceuticals USA, INC. | $13.65 | 2024 | Austedo Xr |
| Uswm, LLC | $13.26 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $11.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Shores listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.